DaVita (DVA) Proxy filing summary

Executive summary

• Achieved key milestones in 2025, including profitability in Integrated Kidney Care, international expansion, and strong clinical outcomes, despite challenges such as a cybersecurity incident and supply chain disruptions.

• Maintained financial performance in line with long-term growth targets: 3–7% adjusted operating income growth and 8–14% adjusted diluted EPS growth.

• Repurchased 12.7 million shares, reducing outstanding share count by 15% year-over-year.

• Continued high teammate engagement (85%) and investment in workforce development programs.

Voting matters and shareholder proposals

• Stockholders will vote on the election of nine director nominees, ratification of KPMG LLP as independent auditor for 2026, and an advisory say-on-pay vote for executive compensation.

• Board recommends voting FOR all proposals.

• Proxy access allows stockholders with 3% ownership for 3 years to nominate directors.

Board of directors and corporate governance

• Board consists of nine nominees, eight of whom are independent; average tenure is 6.8 years.

• Board Chair is an independent director; annual board and committee evaluations are conducted.

• Board diversity includes a mix of gender, racial, and professional backgrounds.

• Stockholders can call special meetings at a 10% ownership threshold; no poison pill in place.

• Mandatory retirement age for directors is 75, with exceptions possible.